Literature DB >> 26920351

MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics.

Jessica Oliboni Scapineli1, Lucieli Ceolin1, Márcia Khaled Puñales2, José Miguel Dora1, Ana Luiza Maia3.   

Abstract

Multiple endocrine neoplasia type 2A (MEN2A) may be rarely associated with cutaneous lichen amyloidosis (CLA), a skin lesion located in the interescapular region. Here, we describe 3 MEN2A-related CLA kindred and perform a systematic review (SR) of the literature on clinical, biochemical and molecular characteristics of MEN2A-related CLA patients. Thirty-eight patients with MEN2A-related CLA followed at our institution were evaluated. The median age at MEN2A diagnosis in our cohort was 25 (13-41) years, 68 % were women and all harbored codon 634 RET mutations. The literature search resulted in 20 publications that contributed with 25 MEN2A families and 214 individuals. The mean age of MEN2A diagnosis was 31 ± 17 years, with 77 % women. The mean age reported by patients to initial skin lesion suggestive to CLA was 20 ± 13 years. All but two kindred harbored mutations at codon 634: C634R 7 kindred (35 %), C634Y 5 kindred (25 %), C634W 3 kindred (15 %), C634G 1 kindred (5 %), V804M 1 kindred (5 %) and S891A 1 kindred (5 %). Most interesting, the standardized CLA prevalence was higher in women (2.3/1.0, P < 0.005). The overall reported prevalence of medullary thyroid carcinoma, CLA, pheochromocytoma and hyperparathyroidism was 94, 51, 30 and 16 %, respectively. SR of literature indicates that MEN2A-related CLA is more frequent in women and presents a high penetrance, being the second most frequent manifestation of the syndrome, preceded only by MTC.

Entities:  

Keywords:  Cutaneous lichen amyloidosis; MEN2A; Meta-analysis; Multiple endocrine neopasia type 2; Systematic review

Mesh:

Substances:

Year:  2016        PMID: 26920351     DOI: 10.1007/s10689-016-9892-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  37 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

3.  Multiple endocrine neoplasia type 2A/localized cutaneous lichen amyloidosis associated with malignant pheochromocytoma and ganglioneuroma.

Authors:  S Gullu; A Gursoy; M F Erdogan; S Dizbaysak; G Erdogan; N Kamel
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

4.  Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.

Authors:  Ana Luiza Maia; Debora R Siqueira; Marco A V Kulcsar; Alfio J Tincani; Glaucia M F S Mazeto; Lea M Z Maciel
Journal:  Arq Bras Endocrinol Metabol       Date:  2014-10

5.  RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia.

Authors:  R M Hofstra; R H Sijmons; T Stelwagen; R P Stulp; B G Kousseff; C J Lips; P M Steijlen; P C Van Voorst Vader; C H Buys
Journal:  J Invest Dermatol       Date:  1996-08       Impact factor: 8.551

6.  Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma.

Authors:  H J Karga; M K Karayianni; D A Linos; S C Tseleni; K D Karaiskos; P D Papapetrou
Journal:  Eur J Endocrinol       Date:  1998-10       Impact factor: 6.664

7.  Frequent association between MEN 2A and cutaneous lichen amyloidosis.

Authors:  Uberta Verga; Laura Fugazzola; Stefano Cambiaghi; Chiara Pritelli; Elvio Alessi; Donatella Cortelazzi; Emanuela Gangi; Paolo Beck-Peccoz
Journal:  Clin Endocrinol (Oxf)       Date:  2003-08       Impact factor: 3.478

8.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

9.  Characterization of the ret proto-oncogene products expressed in mouse L cells.

Authors:  M Takahashi; N Asai; T Iwashita; T Isomura; K Miyazaki; M Matsuyama
Journal:  Oncogene       Date:  1993-11       Impact factor: 9.867

10.  Rare manifestation of multiple endocrine neoplasia type 2A & cutaneous lichen amyloidosis in a family with RET gene mutation.

Authors:  Shweta Birla; Rajiv Singla; Arundhati Sharma; Nikhil Tandon
Journal:  Indian J Med Res       Date:  2014-05       Impact factor: 2.375

View more
  10 in total

1.  The RET C611Y mutation causes MEN 2A and associated cutaneous lichen amyloidosis.

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Lie Cao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-07-26       Impact factor: 3.335

Review 2.  Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.

Authors:  Samuel A Wells
Journal:  Endocr Relat Cancer       Date:  2017-11-15       Impact factor: 5.678

Review 3.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 4.  Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

5.  Multiple endocrine neoplasia type 2A with cutaneous lichen amyloidosis.

Authors:  Rakhi Malhotra; Hiya Boro; Shamim Ahmed Shamim; Rajesh Khadgawat
Journal:  BMJ Case Rep       Date:  2020-08-26

6.  Medullary Thyroid Carcinoma With Exon 2 p.L56M RET Variant: Clinical Particular Features in Two Patients.

Authors:  Rosa M Paragliola; Rosa M Lovicu; Giampaolo Papi; Ettore Capoluongo; Angelo Minucci; Giulia Canu; Alfredo Pontecorvi; Salvatore M Corsello
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-19       Impact factor: 5.555

Review 7.  5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Authors:  Shu-Yuan Li; Yi-Qiang Ding; You-Liang Si; Mu-Jin Ye; Chen-Ming Xu; Xiao-Ping Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

Review 8.  Primary Localized Cutaneous Amyloidosis of Keratinocyte Origin: An Update with Emphasis on Atypical Clinical Variants.

Authors:  Lamiaa Hamie; Isabelle Haddad; Nourhane Nasser; Mazen Kurban; Ossama Abbas
Journal:  Am J Clin Dermatol       Date:  2021-07-21       Impact factor: 7.403

9.  Hereditary medullary thyroid carcinoma syndromes: experience from western India.

Authors:  Chakra Diwaker; Vijaya Sarathi; Sanjeet Kumar Jaiswal; Ravikumar Shah; Anuja Deshmukh; Anand Ebin Thomas; Gagan Prakash; Gaurav Malhotra; Virendra Patil; Anurag Lila; Nalini Shah; Tushar Bandgar
Journal:  Fam Cancer       Date:  2021-01-04       Impact factor: 2.375

10.  The RET C611Y mutation causes MEN 2A and associated cutaneous

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Li Zao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.